GSK’s common respiratory virus vaccine shows potential in adults aged 50-59

Oct 25, 2023 3:06 PM PHT

Reuters

SUMMARY

This is AI generated summarization, which may have errors. For context, always refer to the full article.

GSK. The GlaxoSmithKline logo is seen in this illustration, August 10, 2022.

Dado Ruvic/Reuters

GSK's Arexvy meets the primary goal in the Phase-III trial of eliciting an immune response in adults 50-59 who are at an increased risk of catching the virus due to certain underlying medical conditions

GSK said its vaccine for respiratory syncytial virus (RSV) showed positive preliminary results in a late-stage trial to protect adults aged 50 to 59 from the disease that causes thousands of hospitalizations and deaths annually.

The British drugmaker’s shot, called Arexvy, met the primary goal in the Phase-III trial of eliciting an immune response in adults of the reported age group who are at an increased risk of catching the virus due to certain underlying medical conditions, the company said on Wednesday.

RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.

The shot has already been approved in the United States, Europe, Japan and other countries to protect adults aged 60 years and older. – Rappler.com